Pasar al contenido principal

BIOLOGIA ESTRUCTURAL DE SISTEMAS DE REGULACION DE LA EXPRESION GENICA Y DE TRANSLOCACION DEL DNA

BFU2017-83720-P

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structure-driven discovery of α,γ-diketoacid inhibitors against UL89 herpesvirus terminase

  • Bongarzone, Salvatore
  • Nadal, Marta
  • Kaczmarska, Zuzanna
  • Machón, Cristina
  • Álvarez, Mercedes
  • Albericio, Fernando
  • Coll, Miquel
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes., Human cytomegalovirus (HCMV) is an opportunistic pathogen causing a variety of severe viral infections, including irreversible congenital disabilities. Nowadays, HCMV infection is treated by inhibiting the viral DNA polymerase. However, DNA polymerase inhibitors have several drawbacks. An alternative strategy is to use compounds against the packaging machinery or terminase complex, which is essential for viral replication. Our discovery that raltegravir (1), a human immunodeficiency virus drug, inhibits the nuclease function of UL89, one of the protein subunits of the complex, prompted us to further develop terminase inhibitors. On the basis of the structure of 1, a library of diketoacid (α,γ-DKA and β,δ-DKA) derivatives were synthesized and tested for UL89-C nuclease activity. The mode of action of α,γ-DKA derivatives on the UL89 active site was elucidated by using X-ray crystallography, molecular docking, and in vitro experiments. Our studies identified α,γ-DKA derivative 14 able to inhibit UL89 in vitro in the low micromolar range, making 14 an optimal candidate for further development and virus-infected cell assay., S.B. was supported by COFUND/Marie Curie fellowship (European Commission FP7). CM was supported by the RYC fellowship (grant RYC2011-09071) from the Ministerio de Economia y Competividad (MINECO). The Institute for Research in Biomedicine Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO. The work was partially supported by grants from the MINECO (grants BFU2011-22588, CTQ2012-30930, CTQ2015-67870P, BFU2014-53550-P, BFU2017-83720-P, Marí a de Maeztu Award of Excellence MDM-2014-0435), the Generalitat de Catalunya (grants 2014 SGR 1530 and 2014 SGR 137) and the European Commission FP7 (Project SILVER-GA no. 260644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Atomic structure of the Epstein-Barr virus portal

  • Machón, Cristina
  • Fàbrega-Ferrer, Montserrat
  • Zhou, Daming
  • Cuervo, Ana
  • Carrascosa, José L.
  • Stuart, David I.
  • Coll, Miquel
© The Author(s) 2019., Herpesviridae is a vast family of enveloped DNA viruses that includes eight distinct human pathogens, responsible for diseases that range from almost asymptomatic to severe and life-threatening. Epstein-Barr virus infects B-cells and epithelial cells, causing infectious mononucleosis, as well as a number of cancers. Epstein-Barr infection cannot be cured since neither vaccine nor antiviral drug treatments are available. All herpesviruses contain a linear double-stranded DNA genome, enclosed within an icosahedral capsid. Viral portal protein plays a key role in the procapsid assembly and DNA packaging. The portal is the entrance and exit pore for the viral genome, making it an attractive pharmacological target for the development of new antivirals. Here we present the atomic structure of the portal protein of Epstein-Barr virus, solved by cryo-electron microscopy at 3.5 Å resolution. The detailed architecture of this protein suggests that it plays a functional role in DNA retention during packaging., This work was partly supported by the Ministry of Science, Innovation and Universities of Spain, grants BFU2014-53550-P and BFU2017-83720-P (to M.C.), BFU 2014-54181 (to J.L.C.), and contracts SEV-2013-0347 (to A.C.), and RYC-2011-09071 (to C.M.). We acknowledge institutional funding through the Spanish Government Centres and Units of Excellence, Severo Ochoa and María de Maeztu awards, to IRB-Barcelona (SEV-2015-0500) and IBMB Structural Biology Unit (MDM-2014-0435), respectively; and from the CERCA Programme of the Catalan Government to IRB-Barcelona. This work has also been supported by iNEXT, grant number 653706, funded by the Horizon 2020 programme of the European Commission.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structures of T7 bacteriophage portal and tail suggest a viral DNA retention and ejection mechanism

  • Cuervo, Ana
  • Fàbrega-Ferrer, Montserrat
  • Machón, Cristina
  • Conesa, José J.
  • Fernández, Francisco J.
  • Pérez-Luque, Rosa
  • Pérez-Ruiz, Mar
  • Pous, Joan
  • Vega, María Cristina
  • Carrascosa, José L.
  • Coll, Miquel
Double-stranded DNA bacteriophages package their genome at high pressure inside a procapsid through the portal, an oligomeric ring protein located at a unique capsid vertex. Once the DNA has been packaged, the tail components assemble on the portal to render the mature infective virion. The tail tightly seals the ejection conduit until infection, when its interaction with the host membrane triggers the opening of the channel and the viral genome is delivered to the host cell. Using high-resolution cryo-electron microscopy and X-ray crystallography, here we describe various structures of the T7 bacteriophage portal and fiber-less tail complex, which suggest a possible mechanism for DNA retention and ejection: a portal closed conformation temporarily retains the genome before the tail is assembled, whereas an open portal is found in the tail. Moreover, a fold including a seven-bladed β-propeller domain is described for the nozzle tail protein., This work was supported by the Ministry of Science, Innovation and Universities of Spain, grants BFU 2014-54181 (to J.L.C.), BFU 2014-53550-P and BFU2017-83720-P (to M.C.), and contracts SEV-2013-0347 (to A.C.) and RYC-2011-09071 (to C.M.). We acknowledge institutional funding through the Spanish Government Centres and Units of Excellence Severo Ochoa and Maria de Maeztu awards to IRB Barcelona (SEV-2015-0500) and IBMB Structural Biology Unit (MDM-2014-0435), respectively, and from the CERCA Programme of the Catalan Government to the IRB Barcelona. This work has also been supported by the European Commission, Horizon 2020 program through iNEXT project (grant number 653706).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Using a partial atomic model from medium- resolution cryo-EM to solve a large crystal structure

  • Fàbrega-Ferrer, Montserrat
  • Cuervo, Ana
  • Fernández, Francisco J.
  • Machón, Cristina
  • Pérez-Luque, Rosa
  • Pous, Joan
  • Vega, María Cristina
  • Carrascosa, José L.
  • Coll, Miquel
Medium-resolution cryo-electron microscopy maps, in particular when they include a significant number of α-helices, may allow the building of partial models that are useful for molecular-replacement searches in large crystallo­graphic structures when the structures of homologs are not available and experimental phasing has failed. Here, as an example, the solution of the structure of a bacteriophage portal using a partial 30% model built into a 7.8 Å resolution cryo-EM map is shown. Inspection of the self-rotation function allowed the correct oligomerization state to be determined, and density-modification procedures using rotation matrices and a mask based on the cryo-EM structure were critical for solving the structure. A workflow is described that may be applicable to similar cases and this strategy is compared with direct use of the cryo-EM map for molecular replacement., The following funding is acknowledged: Ministry of Science, Innovation and Universities of Spain (grant Nos. BFU2014-53550-P and BFU2017-83720-P to Miquel Coll; grant No. BFU2014-54181 to Jose´ L. Carrascosa; contract No. SEV2013-0347 to Ana Cuervo; contract No. RYC-2011-09071 to Cristina Machon; award No. SEV-2015-0500 to IRB Barcelona; award No. MDM-2014-0435 to IBMB Structural Biology Unit); Catalan Government CERCA Programme (grant to IRB Barcelona).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404

  • Fàbrega-Ferrer, Montserrat
  • Herrera Morande, Alejandra Margarita
  • Muriel-Goñi, Sara
  • Pérez-Saavedra, Julia
  • Bueno, P.
  • Castro, Victoria
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Coll, Miquel
Severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2) pose a threat to global public health. The 3C-like main protease (Mpro), which presents structural similarity with the active site domain of enterovirus 3C protease, is one of the best-characterized drug targets of these viruses. Here we studied the antiviral activity of the orally bioavailable enterovirus protease inhibitor AG7404 against SARS-CoV-1 and SARS-CoV-2 from a structural, biochemical, and cellular perspective, comparing it with the related molecule rupintrivir (AG7800). Crystallographic structures of AG7404 in complex with SARS-CoV-1 Mpro and SARS-CoV-2 Mpro and of rupintrivir in complex with SARS-CoV-2 Mpro were solved, revealing that all protein residues interacting with the inhibitors are conserved between the two proteins. A detailed analysis of protein-inhibitor interactions indicates that AG7404 has a better fit to the active site of the target protease than rupintrivir. This observation was further confirmed by biochemical FRET assays showing IC50 values of 47 μM and 101 μM for AG7404 and rupintrivir, respectively, in the case of SARS-CoV-2 Mpro. Equivalent IC50 values for SARS-CoV-1 also revealed greater inhibitory capacity of AG7404, with a value of 29 μM vs. 66 μM for rupintrivir. Finally, the antiviral activity of the two inhibitors against SARS-CoV-2 was confirmed in a human cell culture model of SARS-CoV-2 infection, although rupintrivir showed a higher potency and selectivity index in this assay., This study was supported by the Ministry of Science and Innovation of Spain (grant numbers BFU2017-83720-P and PID-2020-120141GB-I00 to MC) and Spanish National Research Council (grant numbers 2020AEPP116 to MC and PIE-RD-COVID-19 ref. E202020E079 to the CNB-CSIC). We acknowledge institutional funding from the Ministry of Science and Innovation of Spain through the Severo Ochoa Award of Excellence (SEV-2015-0500 and CEX2019-000913-S to IRB Barcelona) and Maria de Maeztu Award (MDM-2014-0435 to IBMB-CSIC Structural Biology Unit), and from the Catalan Government's CERCA Programme (grant to IRB Barcelona). This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global). AHM was supported by National Agency for Research and Development (ANID)/Scholarship Program POSTDOCTORADO BECAS CHILE/2019–74200135. SMG was supported by an FPI fellowship from the Ministry of Science and Innovation of Spain. AG7404 ((E)-(S)-4-((S)-2-{3-[(5-methyl-isoxazole-3-carbonyl)-amino]-2-oxo-2H-pyridin-1-yl}-pent-4-ynoylamino)-5-((S)-2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester) was provided by Pfizer under Pure Compound Grant 63236753. With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000913-S)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structures of pMV158 replication initiator RepB with and without DNA reveal a flexible dual-function protein

  • Machón, Cristina
  • Ruiz-Masó, José A.
  • Amodio, Juliana
  • Boer, Roeland
  • Bordanaba-Ruiseco, Lorena
  • Bury, Katarzyna
  • Konieczny, Igor
  • Solar, Gloria del
  • Coll, Miquel
15 p.-6 fig.1 graph. abst., DNA replication is essential to all living organisms as it ensures the fidelity of genetic material for the next generation of dividing cells. One of the simplest replication initiation mechanisms is the rolling circle replication. In the streptococcal plasmid pMV158, which confers antibiotic resistance to tetracycline, replication initiation is catalysed by RepB protein. The RepB N-terminal domain or origin binding domain binds to the recognition sequence (bind locus) of the double-strand origin of replication and cleaves one DNA strand at a specific site within the nic locus. Using biochemical and crystallographic analyses, here we show how the origin binding domain recognises and binds to the bind locus using structural elements removed from the active site, namely the recognition α helix, and a β-strand that organises upon binding. A new hexameric structure of full-length RepB that highlights the great flexibility of this protein is presented, which could account for its ability to perform different tasks, namely bind to two distinct loci and cleave one strand of DNA at the plasmid origin., Ministry of Science and Innovation of Spain [BFU2017-83720-P, PID2020-120141GB-100 to M.C., 2022AEP028 (RT12018-097114-B-I00), BFU2010-19597 to G.dS.]; RYC fellowship [RYC-2011-09071 to C.M.]; CSIC [2020AEP116 to M.C.]. Funding for open access charge: CSIC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ToxR activates the Vibrio cholerae virulence genes by tethering DNA to the membrane through versatile binding to multiple sites

  • Canals, Albert
  • Pieretti, Simone
  • Muriel-Masanes, Mireia
  • Yaman, Nour El
  • Plecha, Sarah C.
  • Thomson, Joshua J.
  • Fàbrega-Ferrer, Montserrat
  • Pérez-Luque, Rosa
  • Krukonis, Eric S.
  • Coll, Miquel
ToxR, a Vibrio cholerae transmembrane one-component signal transduction factor, lies within a regulatory cascade that results in the expression of ToxT, toxin coregulated pilus, and cholera toxin. While ToxR has been extensively studied for its ability to activate or repress various genes in V. cholerae, here we present the crystal structures of the ToxR cytoplasmic domain bound to DNA at the toxT and ompU promoters. The structures confirm some predicted interactions, yet reveal other unexpected promoter interactions with implications for other potential regulatory roles for ToxR. We show that ToxR is a versatile virulence regulator that recognizes diverse and extensive, eukaryotic-like regulatory DNA sequences, that relies more on DNA structural elements than specific sequences for binding. Using this topological DNA recognition mechanism, ToxR can bind both in tandem and in a twofold inverted-repeat-driven manner. Its regulatory action is based on coordinated multiple binding to promoter regions near the transcription start site, which can remove the repressing H-NS proteins and prepares the DNA for optimal interaction with the RNA polymerase., We wish to thank the personnel of the BL13-XALOC beamline of the ALBA Synchrotron in Cerdanyola del Vallès (Spain). This work was supported by the Ministry of Science, Innovation and Universities of Spain, (BFU2017-83720-P, PID2020-120141GB-I00, and MDM-2014-0435 to M.C.). We gratefully acknowledge institutional funding from the Spanish Ministry of Science and Innovation through the Centres of Excellence Severo Ochoa Award and from the CERCA Programme/Generalitat de Catalunya. This work was also supported by the University of Detroit Mercy School of Dentistry Grant (FRG-2017-02 to E.S.K.) and the NIH Common Fund and Office of Scientific Workforce Diversity under three linked awards (RL5GM118981, TL4GM118983, and 1UL1GM118982) administered by the National Institute of General Medical Sciences., Peer reviewed